An observational study in Type 1 Diabetes Mellitus, sponsored by University of Aarhus. Recruiting at 5 sites in Denmark. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-02-02.
Sponsored by University of Aarhus · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Diabetes Mellitus, Type 1 by University of Aarhus — 6 open to participants now, 6 under way, none of them phase 3. Diabetes Mellitus, Type 1 · University of Aarhus.
Among the 24 studies in Diabetes Mellitus, Type 1 by University of Aarhus, this one is one of 3 that started in 2025, is one of 3 observational ones, and was the 22nd registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →6 of the 24 studies in Diabetes Mellitus, Type 1 by University of Aarhus are open now, in 1 country. Recruiting first, the newest first:
University of Aarhus · Sites in Denmark
Ages 20–70 · Healthy volunteers
University of Aarhus · Sites in Denmark
Ages 18+
University of Aarhus · Sites in Denmark
Ages 18–65 · Healthy volunteers
University of Aarhus
Ages 15–70
University of Aarhus
Ages 18+
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 125 across 791 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 20 across the 21 interventional studies, 12 across the 3 observational. Of the 18 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Aarhus is the lead sponsor of 1,303 studies on the registry; 190 are open to participants now.
1 of the studies in Diabetes Mellitus, Type 1 by University of Aarhus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07172672University of AarhusThe TiMeD-T1D Project | 2027-02-01 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Diabetes Mellitus, Type 1 by University of Aarhus, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to compare cardiac and renal oxygen consumption among subjects with type 1 diabetes treated with either multifactorial intervention or according to the current standard care. Participants are recruited from a main study /the Steno1 study) responsible for the intervention.
The main questions it aims to answer are if a multifactorial intervention in subjects with type 1 diabetes targeting cardiovascular and renal risk factors, will reduce cardiac and renal oxygen demand.
Participants will undergo the following examinations at 0-month, 6-month, and 24-month after enrolling in the main study:
In the MICRON study we will recruit participants from the ongoing CTIS approved Steno 1 study which is a prospective, cluster-randomized multicentre trial of 2000 persons with T1D. The Steno 1 study evaluates cardiovascular and renal effects of a multifactorial intervention vs. standard clinical care in subjects with type 1 diabetes (T1D) and established diabetic kidney disease (DKD), cardiovascular disease (CVD), heart failure, obesity or a >10% 5-year CVD risk using the Steno Risk Engine. The multifactorial intervention includes ambitious blood pressure and lipid targets as well as individualised pharmacological intervention with semglutide, sotagliflozin, and/or finerenone.
For the MICRON study we will recruit 20 persons from the ongoing Steno 1 study receiving multifactorial intervention as well as 20 persons from the Steno 1 study receiving standard care. No additional intervention is used for the MICRON study.
In the MICRON study each participant will undergo both [¹¹C]acetate PET/CT and [⁹⁹mTc]DTPAGFR measurements at baseline (inclusion) and again after 6 and 24 months of treatment (multifactorial intervention vs. standard care). At each of the three visits, blood and urine samples will be collected, along with anthropometric measurements.
The primary outcome variables, myocardial and renal oxygen consumption, will be assessed using [¹¹C]acetate PET/CT using a long axial field-of-view (LAFOV) PET scanner. Given that renal oxygen consumption is influenced by glomerular filtration rate (GFR), we will use [⁹⁹mTc]DTPA to accurately measure and account for variations in GFR when assessing renal oxygen consumption.
Three additional work packages WP2, WP3 and WP4 are to be conducted in collaboration with Steno Diabetes Centre Copenhagen, Monash University, Melbourne, Australia and the Department of Biomedicine, Aarhus University, Aarhus, Denmark investigating: WP2 Fibrosis, WP3 Oxidative stress and inflammation and WP4 Urinary extracellular vesicle proteomics.
The study population for the Steno1 Study is persons with Type 1 Diabetes at the Steno Diabetes Centre and at partner clinics in Region Midt, Denmark. The MICRON study will recruit from these participants.
Steno 1 inclusion criteria:
Steno 1 exclusion criteria:
Additional exclusion criteria in the MICRON study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Receiving the intensive treatment therapy in the Steno 1 Study. This consists of more ambitious blood pressure and lipid targets as well as individualised pharmacological intervention with GLP1 receptor agonist (semglutide), dual SGLT-1/2 inhibitor (sotagliflozin), and/or nonsteroidal mineralocorticoid receptor antagonist (finerenone).
Receiving standart care in the Steno 1 Study.
Myocardial oxygen consumption
Measured by \[11C\]acetate PET/CT Unit: volumen pr mass pr time
Time frame: At baseline (0 month), at 6 months and 24 months.
Renal oxygen consumption
Measured by \[11C\]acetate PET/CT Unit: volumen pr mass pr time
Time frame: At baseline (0 month), at 6 months and 24 months.
Myocardial external efficiency
Measured by \[11C\]acetate PET/CT Unit: %
Time frame: At baseline (0 month), at 6 months and 24 months.
Myocardial perfusion
Measured by \[11C\]acetate PET/CT Unit: volumen pr mass pr time
Time frame: At baseline (0 month), at 6 months and 24 month.
Renal perfusion
Measured by \[11C\]acetate PET/CT Unit: volumen pr mass pr time
Time frame: At baseline (0 month), at 6 months and 24 months.
Amount of markers for oxidative stress and inflammation
Exploratory analysis on pathways of oxidative stress and inflammation known to be involved in diabetic cardiorenal damage. Analysis on blood and urine samples.
Time frame: Samples collected at baseline (0 month), at 6 months and 24 months.
Amount of markers for renal fibrosis
Exploratory measurements of renal extracellular matrix metabolism. Measurement of formation of collagen type III and VI (PRO-C3 and PRO-C6), endotrophin, and the collagen III degradation product C3M in blood and urine.
Time frame: Samples collected at baseline (0 month), at 6 months and 24 months.
Urinary extracellular vesicle
Unbiased, large-scale quantitative proteomic profiling of urinary extracellular vesicles (uEVs). Functional interpretation uses Gene Ontology and pathway enrichment analyses, with emphasis on inflammation, mitochondrial oxygen consumption, and oxidative-stress-related pathways.
Time frame: On urine samples collected at baseline (0 month), at 6 months and 24 months. Differential protein abundance is assessed longitudinally (baseline vs 6 and 24 months) and cross-sectionally between treatments at matched time points.
Glomerular filtration rate
Measured by \[99mTc\]DTPA Unit: ml/(min\*1,73 m\^2)
Time frame: At baseline (0 month), at 6 months and 24 months.
Urine albumin-creatinine ratio
Measured by urine spots Unit: None
Time frame: At baseline (0 month), at 6 months and 24 months. Moreover, results from in-clinic laboratory assessments will be collected during the study period if available.
Blood pressure
Unit: mmHg
Time frame: At baseline (0 month), at 6 months and 24 months.
Plasma glucose
Measured by POCT (Point-of-Care Testing)
Time frame: Will be measured regularly (at least hourly) at the three study visits (baseline, 6 months, and 24 months) to monitor levels during fasting.
Pro-brain natriuretic peptide
Unit: Mass pr volumen
Time frame: At baseline (0 month), at 6 months and 24 months.
Troponin I
Unit: Mass pr volumen
Time frame: At baseline (0 month), at 6 months and 24 months.
Blood lipids
Total cholesterol, LDL, HDL and triglycerides. Unit: Mass pr volumen
Time frame: At baseline (0 month), at 6 months and 24 months.
Liver enzymes
Alanine transaminase (ALAT) and aspartate transaminase (ASAT). Unit: Mass pr volumen.
Time frame: At baseline (0 month), at 6 months and 24 months.
Hemoglobin A1c
Unit: mmol/mol
Time frame: At baseline (0 month), at 6 months and 24 months.
Thyroid-stimulating hormone (TSH)
Unit: amount pr volumen.
Time frame: At baseline (0 month), at 6 months and 24 months.
Blood ketones
Unit: amount per volumen
Time frame: At baseline (0 month), at 6 months and 24 months.
eGFR
Unit: mL/min/1,73 m2
Time frame: At baseline (0 month), at 6 months and 24 months.
Electrolytes
Sodium + Potassium Unit: mass pr
Time frame: At baseline (0 month), at 6 months and 24 months.
Trombocytes
Unit: amount pr volumen.
Time frame: At baseline (0 month), at 6 months and 24 months.
Plan to share: Undecided
Started Oct 2025 (actual). Primary completion is estimated for Jul 2028, 33 months after the start.
Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's planned 33 months is close to that.
Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.